Document:

Amendment to Amended and Restated Preferred Shares Rights Agreement

 Exhibit 4.1 
 AMENDMENT TO PREFERRED SHARES RIGHTS AGREEMENT 
 THIS AMENDMENT TO THE AMENDED AND RESTATED PREFERRED
SHARES RIGHTS AGREEMENT (this “Amendment”), dated as of June 29, 2009, between Cell Genesys, Inc., a Delaware corporation (the “Company”), and Computershare Trust Company, N.A., as successor rights agent to Fleet National
Bank (the “Rights Agent”), amends that certain Amended and Restated Preferred Shares Rights Agreement, dated as of July 27, 2000 (the “Rights Agreement”). 
 WHEREAS, the Company is entering into an Agreement and Plan of Merger (as the same may be amended from time to time, the “Merger Agreement”) by
and between the Company and BioSante Pharmaceuticals, Inc., a Delaware corporation (“Parent”); 
 WHEREAS, the Merger Agreement
provides for the acquisition by Parent of the Company by means of a direct merger of the Company into Parent (the “Merger”), as a result of which (i) each outstanding share of common stock of the Company (the “Shares”) will
be converted into the right to receive a number of shares of the Common Stock of Parent (the “Parent Common Stock”) equal to 0.1615 of a share of Parent Common Stock (the “Exchange Ratio”), which may be adjusted pursuant to the
Merger Agreement, (ii) the Specified Company Stock Options (as defined in the Merger Agreement) will be assumed and converted into options to acquire Parent Common Stock on the basis of the Exchange Ratio, and (iii) all Company Stock
Options (as defined in the Merger Agreement) other than Specified Company Stock Options will terminate at the effective time of the Merger; 
 WHEREAS, the Company desires to amend the Rights Agreement in connection with the execution and delivery of the Merger Agreement; 
 WHEREAS, the Board of Directors of the Company has (i) determined that it is in the best interests of the Company and its stockholders that the Rights Agreement be amended as set forth below, (ii) approved this Amendment and
(iii) authorized its appropriate officers to execute and deliver the same to the Rights Agent; 
 WHEREAS, pursuant to Section 27
of the Rights Agreement, the Company may from time to time supplement or amend the Rights Agreement in accordance with the provisions of Section 27 thereof and the Company desires and directs the Rights Agent to execute this Amendment; and

 WHEREAS, the Distribution Date has not yet occurred. 

 NOW, THEREFORE, in accordance with the procedures for amendment of the Rights Agreement set forth in
Section 27 thereof, and in consideration of the foregoing and the mutual agreements herein set forth, the parties hereby agree as follows: 
 1. Section 1(a) of the Rights Agreement is amended by adding the following clause at the end of Section 1(a): 
 “Additionally, BioSante Pharmaceuticals, Inc., a Delaware corporation (“BioSante”), or any Affiliate or Associate thereof, notwithstanding anything in this Agreement to the contrary, shall not be deemed to be an
“Acquiring Person (and no Distribution Date or Triggering Event shall be deemed to occur) as a result of (A) the approval, execution or delivery of that certain Agreement and Plan of Merger, dated as of June 29, 2009, by and between
the Company and BioSante (as the same may be amended from time to time, the “Merger Agreement”), including the approval, execution and delivery of any amendments thereto, (B) the approval, execution or delivery of that certain voting
undertaking by and between the Company, BioSante and Stephen A. Sherwin, M.D. (the “Voting Undertaking”); (C) the consummation of the Merger (as defined in the Merger Agreement), (D) the conversion of shares pursuant to the
Merger Agreement, (E) the announcement of the Merger Agreement or the Merger (as defined in the Merger Agreement), or (F) the consummation of any other transaction contemplated by the Merger Agreement.” 
 2. Section 1(r) of the Rights Agreement is amended and restated in its entirety to read as follows: 
 ““FINAL EXPIRATION DATE” shall mean the earlier to occur of (i) July 27, 2010 or (ii) immediately prior to the Effective
Time (as such term is defined in the Merger Agreement) of the Merger.” 
 3. Section 1(hh) of the Rights Agreement is hereby
amended by adding as the final sentence thereto the following: 
 “Notwithstanding anything in this Agreement to the contrary, no Shares
Acquisition Date shall be deemed to have occurred solely as a result of (i) the approval, execution or delivery of the Merger Agreement, including the approval, execution and delivery of any amendments thereto, (ii) approval, execution or
delivery of the Voting Undertaking, (iii) the consummation of the Merger (as such term is defined in the Merger Agreement), (iv) the conversion of shares pursuant to the Merger Agreement, (v) the announcement of the Merger Agreement
or the Merger (as such term is defined in the Merger Agreement), or (vi) the consummation of any other transaction contemplated by the Merger Agreement.” 
 4. Section 26 of the Rights Agreement is hereby amended to update the contact information for the Company, Company counsel and the Rights Agent as follows: 
 Company: 
 Cell Genesys, Inc. 
 400 Oyster Point Boulevard, Suite 525 
 South
San Francisco, CA 94080 
 Attention: President 

 With copies to: 
 Shearman & Sterling LLP 
 525 Market Street 
 San Francisco, CA 94105 
 Facsimile No:
(415) 616-1199 
 Email: 
 Attention: Michael J. Kennedy, Esq. 
 Michael S. Dorf, Esq. 
 O’Melveny & Myers LLP 
 2765
Sand Hill Road 
 Menlo Park, CA 94025 
 Facsimile No: (650) 473-2601 
 Email: 
 Attention: Sam Zucker, Esq. 
 Eric C. Sibbitt, Esq. 
 Rights Agent: 
 Computershare Trust Company,
N.A. 
 250 Royall Street 
 Canton, MA 02021 
 Attention: Client Services 
 5. A new Section 35 shall be added and shall read as follows: 
 “Section 35. TERMINATION.
Immediately prior to the Effective Time (as such term is defined in the Merger Agreement), this Agreement shall be terminated and all outstanding Rights shall expire. The Company shall notify the Rights Agent as soon as possible following the
occurrence of the Effective Time.” 
 6. This Amendment shall become effective upon execution of the Merger Agreement by the Company and
BioSante. In the event that the Merger Agreement is terminated by the Company or BioSante in accordance with its terms, the provisions of paragraphs 1, 2, 3, 4 and 5 of this Amendment shall be deemed repealed and deleted without any further action
on the part of the Company or the Rights Agent, and the Company shall notify the Rights Agent of such repeal and deletion as soon as possible following such termination. 
 7. Except as expressly amended hereby, the Rights Agreement remains in full force and effect in accordance with its terms. 
 8. This Amendment to the Rights Agreement shall be governed by and construed in accordance with the laws of the State of Delaware. 

 9. This Amendment may be executed in any number of counterparts and each of such counterparts shall for
all purposes be deemed an original, and all such counterparts shall together constitute but one and the same instrument. A signature to this Amendment transmitted electronically shall have the same authority, effect, and enforceability as an
original signature. 
 10. Except as expressly set forth herein, this Amendment shall not by implication or otherwise alter, modify, amend or
in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Rights Agreement, all of which are ratified and affirmed in all respects and shall continue in full force and effect. 
 11. Capitalized terms used herein but not defined shall have the meanings given to them in the Rights Agreement. 
 12. The Company hereby certifies to the Rights Agent that this Amendment is in compliance with Section 27 of the Rights Agreement. 
 [Signature page follows] 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to the Rights Agreement to be duly
executed as of the day and year first above written. 
  

			
	CELL GENESYS, INC.
	a Delaware corporation
		
	By:	 	 /s/    Sharon E. Tetlow

	Name:	 	Sharon E. Tetlow
	Title:	 	Senior Vice President and Chief Financial Officer
	
	COMPUTERSHARE TRUST COMPANY, N.A.
as Rights Agent
		
	By:	 	 /s/    Martin (Jay) J. McHale, Jr.

	Name:	 	Martin (Jay) J. McHale, Jr.
	Title:	 	President, US Equity ServicesVoting Agreement

 Exhibit 10.1 
 VOTING AGREEMENT 
 VOTING AGREEMENT (this “Agreement”), dated as of June 29,
2009, by and among BioSante Pharmaceuticals, Inc., a Delaware corporation (“BioSante”), and the undersigned stockholder (“Stockholder”) of Cell Genesys, Inc., a Delaware corporation (the “Company”),
identified on the signature page hereto. 
 R E C I T A L S: 
 WHEREAS, the Company and BioSante are entering into an Agreement and Plan of Merger (as amended from time to time, the “Merger
Agreement”), dated as of the date hereof, providing for, among other things, the merger of the Company with and into BioSante, with BioSante continuing as the surviving corporation (the “Merger”); 
 WHEREAS, as of the date hereof, Stockholder is the Beneficial Owner (as defined below) of, and has the sole right to vote and dispose of, that number of
shares of common stock (the “Company Shares”) of the Company set forth beside Stockholder’s name on Schedule A hereto; and 
 WHEREAS, concurrently with the entry by the Company and BioSante into the Merger Agreement, and as a condition and inducement to the willingness of BioSante to enter into the Merger Agreement and incur the obligations set forth therein,
BioSante has required that Stockholder enter into this Agreement; 
 NOW, THEREFORE, in consideration of the foregoing and the mutual
representations, warranties, covenants and agreements contained herein, the parties hereto, intending to be legally bound, hereby agree as follows: 
 ARTICLE I 
 DEFINITIONS 
 Capitalized terms used but not defined in this Agreement are used in this Agreement with the meanings given to such terms in the Merger Agreement. In addition, for purposes of this Agreement: 
 “Affiliate” means, with respect to any specified person, a person who, at the time of determination, directly or indirectly through one
or more intermediaries, controls, or is controlled by, or is under common control with, such specified person. For purposes of this Agreement, with respect to Stockholder, “Affiliate” shall not include the Company and the persons
that directly, or indirectly through one or more intermediaries, are controlled by the Company. For the avoidance of doubt, no officer or director of the Company shall be deemed an Affiliate of another officer or director of the Company by virtue of
his or her status as an officer or director of the Company. 
 “Beneficially Owned” or “Beneficial
Ownership” with respect to any securities means having beneficial ownership of such securities (as determined pursuant to Rule 13d-3 

 
under the Exchange Act, disregarding the phrase “within 60 days” in paragraph (d)(1)(i) thereof), including pursuant to any agreement,
arrangement or understanding, whether or not in writing. Without duplicative counting of the same securities, securities Beneficially Owned by a person shall include securities Beneficially Owned by (i) all Affiliates of such person, and
(ii) all other persons with whom such person would constitute a “group” within the meaning of Section 13(d) of the Exchange Act and the rules promulgated thereunder. 
 “Beneficial Owner” with respect to any securities means a person that has Beneficial Ownership of such securities. 
 “person” shall have the meaning ascribed thereto in the Merger Agreement. 
 “Subject Shares” means, with respect to Stockholder, without duplication, (i) the Company Shares owned by Stockholder on the date
hereof as described on Schedule A, and (ii) any additional Company Shares acquired by Stockholder or over which Stockholder acquires Beneficial Ownership from and after the date hereof, whether pursuant to existing stock option agreements or
otherwise. 
 “Transfer” means, with respect to a security, the sale, transfer, pledge, hypothecation, encumbrance,
assignment or disposition of such security or the Beneficial Ownership thereof, and each option, agreement, arrangement or understanding, whether or not in writing, to effect any of the foregoing. As a verb, “Transfer” shall have a
correlative meaning. 
 ARTICLE II 
 COVENANTS OF STOCKHOLDER 
 Section 2.1 Irrevocable Proxy. Concurrently with the execution of this Agreement,
Stockholder agrees to deliver to BioSante a proxy in the form attached hereto as Exhibit A (the “Proxy”), which shall be irrevocable to the extent provided in Section 212 of the Delaware General Corporation Law (the
“DGCL”), with respect to the Subject Shares referred to therein. 
 Section 2.2 Agreement to Vote. 

(a) At any meeting of the stockholders of the Company held prior to the Expiration Date (as defined in Section 5.13), however called, and at every
adjournment or postponement thereof prior to the Expiration Date, or in connection with any written consent of, or any other action by, the stockholders of the Company given or solicited prior to the Expiration Date, Stockholder shall vote, or
provide a consent with respect to, all of the Subject Shares entitled to vote or to consent thereon (i) in favor of the adoption of the Merger Agreement, and any actions required in furtherance thereof and (ii) against any Acquisition
Proposal, against any amendment of the Company’s Certificate of Incorporation or Bylaws or any other proposal or transaction involving the Company, the purpose of which amendment or other proposal or transaction is to delay, prevent or nullify
the Merger or the transaction contemplated by the Merger Agreement or change in any manner the voting rights of any capital stock of the Company, and against any other action or agreement that would result in a breach in any material respect of any
covenant, representation or warranty or any other obligation or agreement of the Company under the Merger Agreement. 
  

 2 

 (b) Stockholder shall not enter into any agreement with any person (other than BioSante) prior to the
Expiration Date (with respect to periods prior to or after the Expiration Date) directly or indirectly to vote, grant any proxy or give instructions with respect to the voting of, the Subject Shares in respect of the matters described in
Section 2.2 hereof, or the effect of which would be inconsistent with or violative of any provision contained in this Section 2.2. Any vote or consent (or withholding of consent) by Stockholder that is not in accordance with this
Section 2.2 shall be considered null and void, and the provisions of the Proxy shall be deemed to take immediate effect. 
 Section 2.3 Revocation of Proxies; Cooperation. Stockholder agrees as follows: 
 (a) Stockholder hereby
represents and warrants that any proxies heretofore given in respect of the Subject Shares with respect to the matters described in Section 2.2(a) hereof are not irrevocable, and Stockholder hereby revokes any and all prior proxies with respect
to such Subject Shares as they relate to such matters. Prior to the Expiration Date, Stockholder shall not directly or indirectly grant any proxies or powers of attorney with respect to the matters set forth in Section 2.2(a) hereof (other than
to BioSante), deposit any of the Subject Shares or enter into a voting agreement (other than this Agreement) with respect to any of the Subject Shares relating to any matter described in Section 2.2(a). 
 (b) Stockholder will (i) use all reasonable efforts to cooperate with the Company and BioSante in connection with the transactions
contemplated by the Merger Agreement, and (ii) provide any information reasonably requested by the Company or BioSante for any regulatory application or filing sought for such transactions. 
 Section 2.4 No Solicitation. 
 (a) Stockholder acknowledges that the Company is subject to the non-solicitation prohibitions set forth in Section 7.05 of the Merger Agreement and that the Stockholder has read and understands the terms thereof.

 (b) Notwithstanding anything to the contrary contained in this Agreement, (i) the provisions of this Section 2.4
apply solely to Stockholder when acting in his, her or its capacity as a stockholder of the Company and not when acting as an officer or director of the Company (it being understood that the Company has separate and independent obligations to
BioSante under the Merger Agreement, including, without limitation, Section 7.05 thereof); and (ii) none of the provisions of this Section 2.4 shall be construed to prohibit, limit or restrict Stockholder from exercising
Stockholder’s fiduciary duties to the Company and/or its stockholders by voting as a director or taking any other action whatsoever in Stockholder’s capacity as a director or officer of the Company. 
 Section 2.5 No Transfer of Subject Shares; Publicity. Stockholder agrees that: 
 (a) Stockholder (i) shall not Transfer or agree to Transfer any of the Subject Shares or, with respect to any matter described in
Section 2.2(a), grant any proxy or 

  

 3 

 
power-of-attorney with respect to any of the Subject Shares, (ii) shall take all action reasonably necessary to prevent creditors in respect of any
pledge of the Subject Shares from exercising their rights under such pledge, and (iii) shall not take any action that would make in a material respect any of its representations or warranties contained herein untrue or incorrect or would have
the effect of preventing or disabling the Stockholder from performing any of its material obligations hereunder. Notwithstanding the foregoing, Stockholder may Transfer and agree to Transfer any of the Subject Shares provided that each person to
which any such Subject Shares are Transferred shall have (x) executed a counterpart of this Agreement and a Proxy in the form attached hereto as Exhibit A (with such modifications as BioSante may reasonably request), and (y) agreed in
writing to hold such Subject Shares subject to all of the terms and conditions set forth in this Agreement. 
 (b) Unless
required by applicable Law or permitted by the Merger Agreement, Stockholder shall not, and shall not authorize or direct any of its Affiliates or Representatives to, make any press release or public announcement with respect to this Agreement or
the Merger Agreement or the transactions contemplated hereby or thereby, without the prior written consent of BioSante in each instance. 
 ARTICLE III 
 REPRESENTATIONS, WARRANTIES AND ADDITIONAL COVENANTS 
 OF STOCKHOLDER 
 Stockholder represents, warrants and covenants to BioSante that: 
 Section 3.1 Ownership. Stockholder is the sole
Beneficial Owner and the record and legal owner of the Subject Shares identified on Schedule A and such shares constitute all of the capital stock of the Company Beneficially Owned by Stockholder. Stockholder has good and valid title to all of such
shares, free and clear of all Liens, claims, options, proxies, voting agreements and security interests and has the sole right to such Subject Shares and there are no restrictions on rights of disposition or other Liens pertaining to such Subject
Shares. None of the Subject Shares is subject to any voting trust or other contract with respect to the voting thereof, and no proxy, power of attorney or other authorization has been granted with respect to any of such Subject Shares. 

Section 3.2 Authority and Non-Contravention. 
 (a) Stockholder is an individual, and not a corporation, limited liability company, partnership, trust or other such entity. Stockholder has all necessary legal capacity to execute and deliver this Agreement and to
perform its obligations hereunder and to consummate the transactions contemplated hereby. 
 (b) Assuming due authorization, execution and
delivery of this Agreement by BioSante, this Agreement has been duly and validly executed and delivered by Stockholder and constitutes the legal, valid and binding obligation of Stockholder, enforceable against Stockholder in accordance with its
terms except (i) to the extent limited by applicable bankruptcy, insolvency or similar laws affecting creditors’ rights and (ii) the remedy of specific performance and injunctive and other forms of equitable relief may be subject to
equitable defenses and to the discretion of the court before which any proceeding therefor may be brought. 
  

 4 

 (c) Stockholder is not nor will it be required to make any filing with or give any notice to, or to
obtain any consent from, any person in connection with the execution, delivery or performance of this Agreement or obtain any permit or approval from any Governmental Authority for any of the transactions contemplated hereby, except to the extent
required by Section 13 or Section 16 of the Exchange Act and the rules promulgated thereunder. 
 (d) Neither the execution and
delivery of this Agreement by Stockholder nor the consummation of the transactions contemplated hereby will directly or indirectly (whether with notice or lapse of time or both) (i) conflict with, result in any violation of or constitute a
default by Stockholder under any mortgage, bond, indenture, agreement, instrument or obligation to which Stockholder is a party or by which it or any of the Subject Shares are bound, or violate any permit of any Governmental Authority, or any Law or
Order to which Stockholder, or any of the Subject Shares, may be subject, or (ii) result in the imposition or creation of any Lien upon or with respect to any of the Subject Shares; except, in each case, for conflicts, violations, defaults or
Liens that would not individually or in the aggregate be reasonably expected to prevent or materially impair or delay the performance by the Stockholder of its obligations hereunder. 
 (e) Stockholder has sole voting power and sole power to issue instructions with respect to the matters set forth in Article II hereof and sole power to
agree to all of the matters set forth in this Agreement, in each case with respect to all of the Subject Shares, with no limitations, qualifications or restrictions on such rights. 
 Section 3.3 Total Shares. Except as set forth on Schedule A, Stockholder is not the Beneficial Owner of, and does not have (whether
currently, upon lapse of time, following the satisfaction of any conditions, upon the occurrence of any event or any combination of the foregoing) any right to acquire, and has no other interest in or voting rights with respect to, any Company
Shares or any securities convertible into or exchangeable or exercisable for Company Shares. 
 Section 3.4 Reliance. Stockholder
understands and acknowledges that BioSante is entering into the Merger Agreement in reliance upon Stockholder’s execution, delivery and performance of this Agreement. 
 ARTICLE IV 
 REPRESENTATIONS, WARRANTIES AND COVENANTS OF BIOSANTE 
 BioSante represents, warrants and covenants to Stockholder that, assuming due authorization, execution and delivery of this Agreement by Stockholder,
this Agreement constitutes the legal, valid and binding obligation of BioSante, enforceable against BioSante in accordance with its terms, except (i) to the extent limited by applicable bankruptcy, insolvency or similar laws affecting
creditors’ rights and (ii) the remedy of specific performance and injunctive and other forms of equitable relief may be subject to equitable defenses and to the discretion of the court before which any proceeding therefor may be brought.
BioSante has the corporate power and authority to execute and deliver this Agreement and to perform its 

  

 5 

 
obligations hereunder. The execution and delivery by BioSante of this Agreement and the consummation by BioSante of the transactions contemplated hereby have
been duly and validly authorized by BioSante and no other corporate proceedings on the part of BioSante are necessary to authorize this Agreement or to consummate the transactions contemplated hereby. This Agreement has been duly and validly
executed and delivered by BioSante. 
 ARTICLE V 
 GENERAL PROVISIONS 
 Section 5.1 No Ownership Interest. Nothing contained in this
Agreement shall be deemed to vest in BioSante or any of its Affiliates any direct or indirect ownership or incidents of ownership of or with respect to the Subject Shares. All rights, ownership and economic benefits of and relating to the Subject
Shares shall remain and belong to Stockholder, and neither BioSante nor any of its Affiliates shall have any authority to manage, direct, superintend, restrict, regulate, govern or administer any of the policies or operations of the Company or
exercise any power or authority to direct Stockholder in the voting of any of the Subject Shares, except as otherwise expressly provided herein or in the Merger Agreement. 
 Section 5.2 Notices. All notices, consents, waivers and other communications under this Agreement shall be in writing (including facsimile or
similar writing) and shall be given: 
 (a) If to BioSante, to: 
 BioSante Pharmaceuticals, Inc. 
 Suite 280 
 111 Barclay Boulevard 
 Lincolnshire, IL 60069 
 Attention: Phillip B. Donenberg 
 Facsimile No: (847) 478-9263 
 with a copy (which shall not constitute notice) to: 
 Oppenheimer Wolff & Donnelly LLP 
 Plaza VII, Suite 3300 
 45 South Seventh Street 
 Minneapolis, MN 55402 
 Attention: Amy E. Culbert, Esq. 
 Facsimile No: (612) 607-7100 
 (b) If to a Stockholder, to Stockholder’s address set forth on Schedule A. 
 or such other address or facsimile number as a party may hereafter specify for the purpose by notice to the other parties hereto. Each notice, consent, waiver or other
communication under this Agreement shall be effective only (a) if given by facsimile, when the facsimile is transmitted to the facsimile number specified in this Section and the appropriate facsimile confirmation is received or (b) if
given by overnight courier or personal delivery when delivered at the address specified in this Section. 
  

 6 

 Section 5.3 Further Actions. Upon the request of any party to this Agreement, the other party
will (a) furnish to the requesting party any additional information, (b) execute and deliver, at their own expense, any other documents and (c) take any other actions as the requesting party may reasonably require to more effectively
carry out the intent of this Agreement. 
 Section 5.4 Entire Agreement and Modification. This Agreement, the Proxy and any other
documents delivered by the parties in connection herewith constitute the entire agreement between the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, both written and oral, between the parties
with respect to its subject matter and constitute (along with the documents delivered pursuant to this Agreement) a complete and exclusive statement of the terms of the agreement between the parties with respect to its subject matter. This Agreement
shall not be amended, supplemented or otherwise modified except by a written document executed by the party against whose interest the modification will operate. The parties shall not enter into any other agreement inconsistent with the terms and
conditions of this Agreement and the Proxy, or that addresses any of the subject matters addressed in this Agreement and the Proxy. 
 Section 5.5 Drafting and Representation. The parties agree that the terms and language of this Agreement were the result of negotiations between the parties and, as a result, there shall be no presumption that any ambiguities in
this Agreement shall be resolved against any party. Any controversy over construction of this Agreement shall be decided without regard to events of authorship or negotiation. 
 Section 5.6 Severability. Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such
jurisdiction, be ineffective to the extent of such prohibition or unenforceability without affecting the validity or enforceability of the remaining provisions hereof. Any such prohibition or unenforceability in any jurisdiction shall not invalidate
or render unenforceable such provision in any other jurisdiction. If any provision of this Agreement is so broad as to be unenforceable, the provision shall be interpreted to be only so broad as is enforceable. 
 Section 5.7 No Third-Party Rights. Stockholder may not assign any of its rights or delegate any of its obligations under this Agreement
without the prior written consent of BioSante. BioSante may not assign any of their rights or delegate any of their obligations under this Agreement with respect to Stockholder without the prior written consent of Stockholder. This Agreement will
apply to, be binding in all respects upon, and inure to the benefit of each of the respective successors, personal or legal representatives, heirs, distributes, devisees, legatees, executors, administrators and permitted assigns of Stockholder and
the successors and permitted assigns of BioSante. Nothing expressed or referred to in this Agreement will be construed to give any person, other than the parties to this Agreement, any legal or equitable right, remedy or claim under or with respect
to this Agreement or any provision of this Agreement except such rights as may inure to a successor or permitted assignee under this Section. 
 Section 5.8 Enforcement of Agreement. Stockholder acknowledges and agrees that BioSante could be damaged irreparably if any of the provisions of this Agreement are not performed in accordance with their specific terms and that
any breach of this Agreement by 

  

 7 

 
Stockholder could not be adequately compensated by monetary damages. Accordingly, Stockholder agrees that, (a) it will waive, in any action for specific
performance, the defense of adequacy of a remedy at Law, and (b) in addition to any other right or remedy to which BioSante may be entitled, at Law or in equity, BioSante will be entitled to enforce any provision of this Agreement by a decree
of specific performance and to temporary, preliminary and permanent injunctive relief to prevent breaches or threatened breaches of any of the provisions of this Agreement, without posting any bond or other undertaking. 
 Section 5.9 Waiver. The rights and remedies of the parties to this agreement are cumulative and not alternative. Neither any failure nor any
delay by a party in exercising any right, power or privilege under this Agreement, the Proxy or any of the documents referred to in this Agreement will operate as a waiver of such right, power or privilege, and no single or partial exercise of any
such right, power or privilege will preclude any other or further exercise of such right, power or privilege or the exercise of any other right, power or privilege. To the maximum extent permitted by Law, (a) no claim or right arising out of
this Agreement, the Proxy or any of the documents referred to in this Agreement can be discharged by one party, in whole or in part, by a waiver or renunciation of the claim or right unless in a written document signed by the other party,
(b) no waiver that may be given by a party will be applicable except in the specific instance for which it is given, and (c) no notice to or demand on one party will be deemed to be a waiver of any obligation of that party or of the right
of the party giving such notice or demand to take further action without notice or demand as provided in this Agreement, the Proxy or the documents referred to in this Agreement. 
 Section 5.10 Governing Law. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto
will be governed by, construed under and interpreted in accordance with the Laws of the State of Delaware, without giving effect to principles of conflicts or choice of law. 
 Section 5.11 Consent to Jurisdiction. Any suit, action or proceeding seeking to enforce any provision of, or based on any matter arising out
of or in connection with, this Agreement, the Proxy or the transactions contemplated hereby or thereby shall be brought exclusively in the United States District Court for the District of Delaware or, if such court does not have jurisdiction over
the subject matter of such proceeding or if such jurisdiction is not available, in the Court of Chancery of the State of Delaware, County of New Castle, and each of the parties hereby consents to the exclusive jurisdiction of those courts (and of
the appropriate appellate courts therefrom) in any suit, action or proceeding and irrevocably waives, to the fullest extent permitted by Law, any objection which it may now or hereafter have to the laying of the venue of any suit, action or
proceeding in any of those courts or that any suit, action or proceeding which is brought in any of those courts has been brought in an inconvenient forum. Process in any suit, action or proceeding may be served on any party anywhere in the world,
whether within or without the jurisdiction of any of the named courts. Without limiting the foregoing, each party agrees that service of process on it by notice as provided in Section 5.2 shall be deemed effective service of process. EACH OF
THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ALL RIGHTS TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT
OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY. 
  

 8 

 Section 5.12 Counterparts. This Agreement may be executed in one or more counterparts, each
of which shall be deemed to be an original, but all of which, taken together, shall constitute one and the same instrument. This Agreement may be executed by facsimile signature (including signatures in Adobe PDF or similar format). 
 Section 5.13 Termination. This Agreement shall terminate upon the earliest of (a) the Effective Time (as defined in the Merger
Agreement), (b) the termination of the Merger Agreement in accordance with Article IX thereof, or (c) written notice by BioSante to Stockholder of the termination of this Agreement (the date of the earliest of the events described in
clauses (a), (b) and (c), the “Expiration Date”). 
 Section 5.14 Expenses. Except as otherwise provided in
this Agreement, all costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such expenses. 
 Section 5.15 Headings; Construction. The headings contained in this Agreement are for reference purposes only and shall not affect in any way
the meaning or interpretation of this Agreement. In this Agreement (a) words denoting the singular include the plural and vice versa, (b) “it” or “its” or words denoting any gender include all genders and (c) the
word “including” shall mean “including without limitation,” whether or not expressed. 
 [SIGNATURE PAGE FOLLOWS]

  

 9 

 IN WITNESS WHEREOF, the parties hereto have caused this Voting Agreement to be duly executed as of the
day and year first above written. 
  

							
	BIOSANTE:	 		 	BIOSANTE PHARMACEUTICALS, INC.
				
		 		 	By:	 	 /s/    Stephen M. Simes

		 		 	Name:	 	Stephen M. Simes
		 		 	Title:	 	Vice Chairman, President and Chief Executive Officer
			
	STOCKHOLDER:	 		 	STEPHEN A. SHERWIN, M.D.
			
		 		 	 /s/    Stephen A. Sherwin

		 		 	Name:	 	Stephen A. Sherwin, M.D.
			
		 		 	Additional Signature (if held jointly):
			
		 		 	  

		 		 	(If held jointly)
			
		 		 	  

		 		 	(Printed Full Name)

 [Signature page to Voting Agreement] 

 SCHEDULE A 
  

			
	 NAME AND
 ADDRESS OF STOCKHOLDER
	 	 COMPANY SHARES
 BENEFICIALLY OWNED

	 Stephen A. Sherwin, M.D.
 3508 Clay Street
 San Francisco, CA 94118
	 	474,6211

  

	1
	 Comprised of shares held by The Sherwin Family Trust. Excludes 1,017,500 shares subject to exercise of options. Also excludes 30,000 shares held by The
Sherwin Irrevocable Children’s Trust (for which Dr. Sherwin does not have beneficial ownership or voting authority). 

 EXHIBIT A 
 IRREVOCABLE PROXY 
 From and after the date hereof and until the Expiration Date (as defined below), the
undersigned stockholder (“Stockholder”) of Cell Genesys, Inc., a Delaware corporation (the “Company”), hereby irrevocably (to the full extent permitted by Section 212 of the Delaware General Corporation Law)
grants to, and appoints, BioSante Pharmaceuticals, Inc., a Delaware corporation (“BioSante”), and any designee of BioSante, and each of them individually, as the sole and exclusive attorney and proxy of the undersigned, with full
power of substitution and resubstitution, to vote the Subject Shares (as defined in the Voting Agreement) of the Stockholder, or grant a consent or approval in respect of the Subject Shares of the Stockholder, in a manner consistent with
Section 2.2 of the Voting Agreement (as defined below). Upon the undersigned’s execution of this Proxy, any and all prior proxies given by the undersigned with respect to any Subject Shares relating to the voting rights expressly provided
herein are hereby revoked and the undersigned agrees not to grant any subsequent proxies with respect to the Subject Shares relating to such voting rights at any time prior to the Expiration Date. 
 This Proxy is irrevocable, is coupled with an interest and is granted pursuant to that certain Voting Agreement (as amended from time to time, the
“Voting Agreement”) of even date herewith, by and among BioSante and Stockholder, and is granted in consideration of BioSante entering into the Merger Agreement (as defined in the Voting Agreement). As used herein, the term
“Expiration Date,” and all capitalized terms used herein and not otherwise defined, shall have the meanings set forth in the Voting Agreement. The Stockholder agrees that this proxy shall be irrevocable until the Expiration Date
and is coupled with an interest sufficient at law to support an irrevocable proxy and given to BioSante as an inducement to enter into the Merger Agreement and, to the extent permitted under applicable law, shall be valid and binding on any person
to whom Stockholder may transfer any of his, her or its Subject Shares in breach of the Voting Agreement. The Stockholder hereby ratifies and confirms all that such irrevocable proxy may lawfully do or cause to be done by virtue hereof.

 The attorneys and proxies named above, and each of them, are hereby authorized and empowered by the undersigned, at any time prior to the
Expiration Date, to act as the undersigned’s attorney and proxy to vote the Subject Shares, and to exercise all voting and other rights of the undersigned with respect to the Subject Shares (including, without limitation, the power to execute
and deliver written consents pursuant to Section 228 of the Delaware General Corporation Law), at every annual, special or adjourned meeting of the stockholders of the Company and in every written consent in lieu of such meeting in a manner
consistent with Section 2.2 of the Voting Agreement. 
 This Proxy shall be binding upon the heirs, estate, executors, personal
representatives, successors and assigns of Stockholder (including any transferee of any of the Subject Shares), and all authority herein conferred or agreed to be conferred shall survive the death or incapacity of the Stockholder. 

 If any provision of this Proxy or any part of any such provision is held under any circumstances to be
invalid or unenforceable in any jurisdiction, then (a) such provision or part thereof shall, with respect to such circumstances and in such jurisdiction, be deemed amended to conform to applicable laws so as to be valid and enforceable to the
fullest possible extent, (b) the invalidity or unenforceability of such provision or part thereof under such circumstances and in such jurisdiction shall not affect the validity or enforceability of such provision or part thereof under any
other circumstances or in any other jurisdiction, and (c) the invalidity or unenforceability of such provision or part thereof shall not affect the validity or enforceability of the remainder of such provision or the validity or enforceability
of any other provision of this Proxy. Each provision of this Proxy is separable from every other provision of this Proxy, and each part of each provision of this Proxy is separable from every other part of such provision. 
 Dated: June 29, 2009 
  

	
	 /s/    Stephen A. Sherwin

	(Signature of Stockholder)
	
	 Stephen A. Sherwin, M.D.

	(Print Name of Stockholder)
	
	 Number of Subject Shares owned of record or Beneficially Owned as of the date of this Proxy:
  
 474,621

  

 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00160-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00160-of-00352.parquet"}]]